Elham Sajjadi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1149538/publications.pdf

Version: 2024-02-01

566801 642321 40 673 15 23 citations h-index g-index papers 41 41 41 463 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine?. Genes, 2020, $11,719$.	1.0	67
2	HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Frontiers in Molecular Biosciences, 2022, 9, 834651.	1.6	63
3	Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. Frontiers in Oncology, 2020, 10, 556718.	1.3	49
4	Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer, 2020, 150, 53-61.	0.9	36
5	Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. Cells, 2021, 10, 1377.	1.8	35
6	CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress. Expert Opinion on Investigational Drugs, 2022, 31, 593-605.	1.9	31
7	Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. Advances in Anatomic Pathology, 2019, 26, 270-279.	2.4	29
8	Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. Cancer Treatment Reviews, 2020, 90, 102089.	3.4	27
9	Biomarkers for precision immunotherapy in the metastatic setting: hope or reality?. Ecancermedicalscience, 2020, 14, 1150.	0.6	27
10	Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization. Cancer Cell International, 2021, 21, 266.	1.8	26
11	PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 1461.	1.8	25
12	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	0.9	25
13	Low-risk triple-negative breast cancers: Clinico-pathological and molecular features. Critical Reviews in Oncology/Hematology, 2022, 172, 103643.	2.0	25
14	Mismatch repair testing in breast cancer: the path to tumor-specific immuno-oncology biomarkers. Translational Cancer Research, 2020, 9, 4060-4064.	0.4	24
15	Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 829875.	1.3	19
16	Integrating Biological Advances Into the Clinical Management of Breast Cancer Related Lymphedema. Frontiers in Oncology, 2020, 10, 422.	1.3	17
17	Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor—Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study. Journal of Personalized Medicine, 2021, 11, 1369.	1.1	14
18	Lymphedema Rehabilitation Using Self-Adaptive Inelastic Compression in Breast Cancer: A Proof-of-Principle Study. Applied Sciences (Switzerland), 2021, 11, 1901.	1.3	13

#	Article	IF	Citations
19	Up regulation of MMP9 gene expression in female patients with multiple sclerosis. Human Antibodies, 2017, 24, 59-64.	0.6	11
20	Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. Histology and Histopathology, 2021, , 18376.	0.5	11
21	Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients. Human Antibodies, 2017, 24, 65-70.	0.6	10
22	Mismatch Repair Status Characterization in Oncologic Pathology: Taking Stock of the Real-World Possibilities. Journal of Molecular Pathology, 2021, 2, 93-100.	0.5	10
23	Combined analysis of PTEN, HER2, and hormone receptors status: remodeling breast cancer risk profiling. BMC Cancer, 2021, 21, 1152.	1.1	9
24	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. Journal of Clinical Medicine, 2021, 10, 1412.	1.0	8
25	Understanding the biology of volumetric muscle loss for an individualized exercise rehabilitation approach in breast cancer patients. Current Opinion in Pharmacology, 2021, 58, 27-34.	1.7	8
26	Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study. Frontiers in Oncology, 2021, 11, 723693.	1.3	8
27	Gene expression analysis of noncoding PCA3 gene in patients with chronic myeloid leukemia. Journal of Cancer Research and Therapeutics, 2018, 14, 1079-1082.	0.3	8
28	Mismatch Repair System Genomic Scars in Gastroesophageal Cancers: Biology and Clinical Testing. Gastrointestinal Disorders, 2020, 2, 341-352.	0.4	7
29	Metaplastic breast cancers and triple-negative breast cancers of no special type. European Journal of Cancer Prevention, 2021, Publish Ahead of Print, .	0.6	7
30	VDR and CYP24A1 Expression Analysis in Iranian Relapsing-Remitting Multiple Sclerosis Patients. Cell Journal, 2017, 19, 352-360.	0.2	6
31	A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast. Cancers, 2022, 14, 370.	1.7	6
32	ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality. Future Oncology, 2021, 17, 4607-4618.	1.1	4
33	IFNAR1 expression level in Iranian multiple sclerosis patients treated with IFN-B. Human Antibodies, 2018, 26, 17-22.	0.6	3
34	Detecting and Accommodating Outliers in Meta-Analysis for Evaluating Effect of Albendazole on Ascaris lumbricoides infection. Iranian Red Crescent Medical Journal, 2014, 16, e17648.	0.5	2
35	Commentary: Mismatch Repair Deficiency and Microsatellite Instability in Triple-Negative Breast Cancer: A Retrospective Study of 440 Patients. Frontiers in Oncology, 2021, 11, 735476.	1.3	2
36	Generalization of the Receiver-Operating Characteristic Curve to Determine the Normal Hemoglobin Range Cutoff Points in Pregnant Women. Iranian Red Crescent Medical Journal, 2014, 16, e18318.	0.5	1

#	Article	IF	CITATIONS
37	Abstract PS9-36: Exercise therapy to reduce breast cancer fatigue: Results from the EXPECT study. , 2021, , .		0
38	10P The clinical actionability of PTEN protein and gene expression analysis in HR- and HER2+ breast cancers. Annals of Oncology, 2021, 32, S25.	0.6	0
39	Abstract P2-05-03: Integrated analysis of mismatch repair, PD-L1, and immune microenvironment status in pregnancy-associated breast cancers. , 2020, , .		O
40	Abstract P4-10-15: Whole-body vibration combined with physical exercise to treat aromatase inhibitor-induced musculoskeletal symptoms in breast cancer women: Results of a pilot randomized controlled study. Cancer Research, 2022, 82, P4-10-15-P4-10-15.	0.4	0